Register Login
Register to leave comments
  • News bot Oct. 2, 2025, 3:23 a.m.

    📋 CENTESSA PHARMACEUTICALS PLC (CNTA) - Clinical Trial Update

    Filing Date: 2022-06-02

    Accepted: 2022-06-02 06:33:50

    Event Type: Clinical Trial Update

    Event Details:

    Centessa Pharmaceuticals plc (CNTA) Announces Clinical Trial Update Centessa Pharmaceuticals plc (CNTA) provided an update on its clinical development programs. Clinical Development Highlights:
    • Drug Program: required, medicines
    • Clinical Stage: Phase 3
    • Collaboration: Autosomal Dominant Polycystic Kidney Disease

    🔬 Clinical Development Pipeline (CENTESSA PHARMACEUTICALS PLC):

    Product Type Development Stage Therapeutic Area Source
    Lixivaptan DRUG Phase PHASE3 Polycystic Kidney Disease, Adult ClinicalTrials.gov
    ZF874 DRUG Phase PHASE1 Alpha1 Anti-Trypsin Deficiency ClinicalTrials.gov
    SerpinPC DRUG Phase PHASE2 Hemophilia a ClinicalTrials.gov
    Placebo DRUG Phase PHASE1 Alpha1 Anti-Trypsin Deficiency ClinicalTrials.gov
    LB101 DRUG Phase PHASE1 Advanced Solid Tumor ClinicalTrials.gov
    CBS001 DRUG Phase PHASE1 Chronic Inflammatory Disease ClinicalTrials.gov
    Placebo Tablets OTHER Phase PHASE1 Excessive Daytime Sleepiness ClinicalTrials.gov
    ORX142 Tablets DRUG Phase PHASE1 Excessive Daytime Sleepiness ClinicalTrials.gov
    No Intervention OTHER Preclinical Hemophilia a ClinicalTrials.gov
    ORX750 DRUG Phase PHASE2 Narcolepsy Type 1 ClinicalTrials.gov

    💼 Business Developments:

    • Partnership: Not available
    • Acquisition: Not available
    • Licensing: Not available
    • Regulatory Approval
    • Executive Changes: Not available

    Structured Data:

    • Company Name: Centessa Pharmaceuticals plc
    • CIK: 0001847903
    • Ticker Symbol: CNTA
    • Period End Date: 2022-06-02
    • Document Type: 8-K

Search

News categories